C-Kit non-mutated metastatic melanoma showing positive response to Nilotinib.

Abstract

Melanoma is an aggressive tumor with advanced disease characterized by widespread metastatic lesions and the tumor has traditionally been resistant to most forms of treatment. Indeed, metastatic melanoma has a very poor prognosis with a median survival time of 8-9 months and an estimated 3-year survival rate of less than 15%. Recent advances in our… (More)

Topics

Cite this paper

@article{Alkeraye2016CKitNM, title={C-Kit non-mutated metastatic melanoma showing positive response to Nilotinib.}, author={Salim Alkeraye and Ali Dadban and Catherine Lok and J P Arnault and Guillaume Chaby}, journal={Dermatology online journal}, year={2016}, volume={22 1} }